登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Study of Serplulimab Plus Chemotherapy as Neoadjuvant Therapy for Limited-stage Small Cell Lung Cancer (LS-SCLC)
ClinicalTrials.gov 上登记的一项肺癌开放试验,由广东省人民医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06911606,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 8
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(8 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
Histologically or cytologically confirmed SCLC
入选标准第 3 条
Female patients must meet one of the following conditions: a. Menopause (defined as the absence of menstruation for at least 1 year without other confirmed reasons other than menopause), or b. Have undergone surgical sterilization (removal of ovaries and/or uterus) , or c. Have childbearing potential, but must meet the following requirements: the serum/urine pregnancy test within 7 days before enrollment must be negative, and agree to use contraceptive measures with an annual failure rate of <1% or maintain abstinence (avoiding heterosexual intercourse) (from signing ICF to at least 6 months after the last dose of study drug) (contraceptive methods with annual failure rates <1% include bilateral fallopian tube ligation, male sterilization, correct use of hormonal contraceptives that inhibit ovulation, and hormone-releasing intrauterine contraception devices and copper-containing IUDs or condoms), and you must not breastfeed.
入选标准第 12 条
Male patients must meet the following requirements: Agree to abstain from sex (avoid heterosexual intercourse) or take contraceptive measures, as follows: When the partner is a female of childbearing age or the partner is pregnant, the male patient must agree to abstain from sexual intercourse (avoiding heterosexual intercourse) or take contraceptive measures for at least 6 months during the study treatment period and after the last dose of the study drug. Maintain abstinence or use condoms during the first trimester to prevent embryonic drug exposure. Periodic abstinence (for example, calendar days, ovulation period, basal body temperature or post-ovulation contraceptive method) and in vitro ejaculation are unqualified contraceptive methods
入选标准第 13 条
The end of previous non-systemic anti-tumor treatment must be ≥ 2 weeks from the start of medication, and according to Common Terminology Criteria for Adverse Events (CTCAE) 5.0, treatment-related AEs reverted to grade ≤1 (except grade 2 alopecia).
入选标准第 14 条
Have undergone major surgery within 28 days before the first administration of the study drug. The definition of major surgery in this study: at least 3 weeks of recovery time are required after surgery before the surgery can be treated in this study
排除标准第 17 条
The subject has previously received other antibodies/drugs targeting immune checkpoints, such as PD-1, PD -L1, CTLA-4 and other treatments
排除标准第 18 条
Are participating in other interventional clinical studies, or plan to start treatment in this study less than 28 days from the end of treatment in a previous interventional clinical study
排除标准第 19 条
ECOG score 0-1
入选标准第 8 条
Hepatitis B surface antigen (HBsAg) (-) and hepatitis B core antibody (HBcAb) (-). If HBsAg (+) or HBcAb (+), the hepatitis B virus deoxyribonucleic acid (HBV-DNA) must be <2500 copies/mL or 500 IU/mL before inclusion. Subjects who are HCV antibody (-) or HCV-RNA negative can be enrolled if HCV-RNA is positive, the subject must have alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤ Only 3×ULN can join the group. Subjects who are co-infected with hepatitis B and hepatitis C need to be excluded (positive HBsAg or HBcAb test, and positive HCV antibody test)
入选标准第 10 条
According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1), there is at least one radiologically measurable lesion
入选标准第 7 条
Other active malignant tumors within 5 years or at the same time. Cured localized tumors, such as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ of the prostate, carcinoma in situ of the cervix, and carcinoma in situ of the breast, can be enrolled
排除标准第 3 条
Human immunodeficiency virus (HIV) infection, HIV antibody test results are positive
排除标准第 9 条
Hepatitis B (HBsAg or HBcAb test is positive, and HBV-DNA test is positive), Hepatitis C (HCV antibody test is positive, and HCV-RNA test is positive). Subjects with co-infection of hepatitis B and hepatitis C (positive HBsAg or HBcAb test, and positive HCV antibody test). Note: Hepatitis B patients who have been stabilized by antiviral treatment (HBV-DNA ≤ 2500 copies/mL or 500IU/mL) can be enrolled
排除标准第 12 条
Pregnant or lactating women
排除标准第 22 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义)。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06911606,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Voluntarily participate in clinical research and sign written informed consent Male or female patients aged 18-75 years old (including the critical value) Histologically or cytologically confirmed SCLC Clinically diagnosed as IIB-IIIB ( N2) stage (AJCC 8th edition cancer staging) Patients who have not received systemic anti-tumor treatment or chest radiotherapy in the past By Surgeons evaluate patients who have no contraindications to surgery According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1), there is at least one radiologically measurable lesion ECOG score 0-1 Expected survival time > 6 months Hepatitis B surface antigen (HBsAg) (-) and hepatitis B core antibody (HBcAb) (-). If HBsAg (+) or HBcAb (+), the hepatitis B virus deoxyribonucleic acid (HBV-DNA) must be <2500 copies/mL or 500 IU/mL before inclusion. Subjects who are HCV antibody (-) or HCV-RNA negative can be enrolled if HCV-RNA is positive, the subject must have alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤ Only 3×ULN can join the group. Subjects who are co-infected with hepatitis B and hepatitis C need to be excluded (positive HBsAg or HBcAb test, and positive HCV antibody test) Laboratory tests within 7 days before the first use of the study drug confirm sufficient organ and bone marrow function, No serious hematopoietic abnormalities, cardiac, liver, renal dysfunction or immune deficiency (no blood transfusion, albumin, recombinant human thrombopoietin or colony-stimulating factor (CSF) treatment within 14 days before the first medication in this study) Female patients must meet one of the following conditions: a. Menopause (defined as the absence of menstruation for at least 1 year without other confirmed reasons other than menopause), or b. Have undergone surgical sterilization (removal of ovaries and/or uterus) , or c. Have childbearing potential, but must meet the following requirements: the serum/urine pregnancy test within 7 days before enrollment must be negative, and agree to use contraceptive measures with an annual failure rate of <1% or maintain abstinence (avoiding heterosexual intercourse) (from signing ICF to at least 6 months after the last dose of study drug) (contraceptive methods with annual failure rates <1% include bilateral fallopian tube ligation, male sterilization, correct use of hormonal contraceptives that inhibit ovulation, and hormone-releasing intrauterine contraception devices and copper-containing IUDs or condoms), and you must not breastfeed. Male patients must meet the following requirements: Agree to abstain from sex (avoid heterosexual intercourse) or take contraceptive measures, as follows: When the partner is a female of childbearing age or the partner is pregnant, the male patient must agree to abstain from sexual intercourse (avoiding heterosexual intercourse) or take contraceptive measures for at least 6 months during the study treatment period and after the last dose of the study drug. Maintain abstinence or use condoms during the first trimester to prevent embryonic drug exposure. Periodic abstinence (for example, calendar days, ovulation period, basal body temperature or post-ovulation contraceptive method) and in vitro ejaculation are unqualified contraceptive methods The end of previous non-systemic anti-tumor treatment must be ≥ 2 weeks from the start of medication, and according to Common Terminology Criteria for Adverse Events (CTCAE) 5.0, treatment-related AEs reverted to grade ≤1 (except grade 2 alopecia).排除标准:Exclusion Criteria:
Mixed SCLC confirmed by histology or cytology Previously received systemic anti-tumor treatment for small cell lung cancer, including but not limited to chemotherapy, immunotherapy, and radiotherapy Other active malignant tumors within 5 years or at the same time. Cured localized tumors, such as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ of the prostate, carcinoma in situ of the cervix, and carcinoma in situ of the breast, can be enrolled Those who are planning to undergo or have received organs in the past or bone marrow transplant patients Pleural effusion, pericardial effusion or ascites requiring clinical intervention Myocardial infarction or poorly controlled arrhythmia (including men with QTc interval) within 6 months before the first administration of the study drug ≥450 ms, women ≥470 ms) (QTc interval is calculated by Fridericia's formula) The subject has uncontrolled or symptomatic hypercalcemia (> 1.5 mmol/L ionized calcium or calcium > 12 mg/dL or Corrected serum calcium > ULN) The patient has grade ≥ 2 CTCAE peripheral neuropathy Human immunodeficiency virus (HIV) infection, HIV antibody test results are positive Suffering from active pulmonary tuberculosis Past and There are currently subjects with interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonia, severely impaired lung function, etc. who are judged by the researcher to be likely to interfere with the detection and treatment of suspected drug-related pulmonary toxicity Hepatitis B (HBsAg or HBcAb test is positive, and HBV-DNA test is positive), Hepatitis C (HCV antibody test is positive, and HCV-RNA test is positive). Subjects with co-infection of hepatitis B and hepatitis C (positive HBsAg or HBcAb test, and positive HCV antibody test). Note: Hepatitis B patients who have been stabilized by antiviral treatment (HBV-DNA ≤ 2500 copies/mL or 500IU/mL) can be enrolled Subjects have known active or suspected autoimmune diseases. Subjects who are in stable condition and do not require systemic immunosuppressant treatment are allowed to enroll Those who have received live vaccine treatment within 28 days before the first dose. However, inactivated viral vaccines are allowed to treat seasonal influenza, but intranasal live attenuated influenza vaccines are not allowed Systemic corticosteroids (> 10 mg/ subjects treated with prednisone effective doses) or other immunosuppressive drugs. However, the following conditions are allowed: in the absence of active autoimmune disease, subjects are allowed to use topical or inhaled steroids and adrenal hormone replacement therapy at a dose of ≤ 10 mg/day prednisone effective dose Any active infection requiring systemic anti-infectious therapy within 14 days before study drug administration, or the subject has a positive RT-PCR test for SARS-CoV-2 infection at enrollment. Subjects with a history of COVID-19 infection must have a negative RT-PCR test before the first administration of the study drug Have undergone major surgery within 28 days before the first administration of the study drug. The definition of major surgery in this study: at least 3 weeks of recovery time are required after surgery before the surgery can be treated in this study The subject has previously received other antibodies/drugs targeting immune checkpoints, such as PD-1, PD -L1, CTLA-4 and other treatments Are participating in other interventional clinical studies, or plan to start treatment in this study less than 28 days from the end of treatment in a previous interventional clinical study Known to have a risk for any monoclonal antibody History of severe allergies Known allergic reaction to carboplatin/cisplatin or etoposide components Pregnant or lactating women Subjects known to have a history of psychotropic drug abuse or drug use According to the researcher's judgment, the subject has other factors that may cause the study to be terminated early.
引自 ClinicalTrials.gov, NCT06911606, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06911606,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。